CN105963369A - Traditional Chinese medicine composition with functions for treating cardiovascular and cerebrovascular diseases, hyperlipidemia, and hyperglycemia - Google Patents
Traditional Chinese medicine composition with functions for treating cardiovascular and cerebrovascular diseases, hyperlipidemia, and hyperglycemia Download PDFInfo
- Publication number
- CN105963369A CN105963369A CN201610300262.9A CN201610300262A CN105963369A CN 105963369 A CN105963369 A CN 105963369A CN 201610300262 A CN201610300262 A CN 201610300262A CN 105963369 A CN105963369 A CN 105963369A
- Authority
- CN
- China
- Prior art keywords
- extract
- chinese medicine
- medicine composition
- flos carthami
- radix notoginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition with functions for treating cardiovascular and cerebrovascular diseases, hyperlipidemia, and hyperglycemia as well as a preparation method and an application thereof, and belongs to the field of traditional Chinese medicine. The traditional Chinese medicine composition comprises the following raw materials: a notoginseng extract product, a safflower extract product and a cistanche extract product, and the raw materials are prepared according to a weight ratio 0.5-2:1-5:4-10, and preferably the notoginseng extract product, the safflower extract product and the cistanche extract product are prepared according to a weight ratio 1:3:7. Tests and researches show that the composition has substantial efficacies for treating cardiovascular and cerebrovascular diseases, hyperlipidemia, hyperglycemia.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of Chinese medicine composition with treatment cardiovascular and cerebrovascular disease, hyperlipidemia and hyperglycemia function and its preparation method and application.
Background technology
Along with the prolongation of people's average life, the improvement of social and economic condition, the raising of living standards of the people, the sickness rate of cardiovascular and cerebrovascular disease, hyperlipidemia and diabetes is all increasing.
Cardiovascular and cerebrovascular disease, such as coronary heart disease, cerebral infarction, being human disease and main causes of death, account for 1/3rd of general mortality rate, in China, its mortality rate alreadys more than cancer, diseased colonies is huge, leaving invalid in survivor, cause huge life threat to patient, the many need of patient are taken medicine for a long time or all the life simultaneously, quality of life is severely impacted, and causes white elephant also to patient home or even entire society.At present, the Chinese medicine and western medicine for the treatment of cardiovascular and cerebrovascular disease is a lot, but the much rarer side effect of Western medicine, and almost without effective method in terms of the treatment of cerebrovascular disease.Chinese medicine has certain characteristic in terms for the treatment of cardiovascular and cerebrovascular disease, and motherland's medical science is thought, nutrient blood multiple abscess in vivo circulates, and moistens the foster vital organs of the human body, extremity bones of the body collectively, to ensure that it plays respective normal physiological function." qi as the commander of blood, blood being the mother of qi；Gas row then blood, the stagnation of QI then blood stasis ".If old or overwork gas consumption, the deficiency of vital energy unable promotion blood operation, blocking venation, muscle arteries and veins loses supports and sends out as apoplexy, clinical signs limbs attach undue importance to one thing to the neglect of the other need not, dysphasia etc..Therefore control suitable benefiting QI for activating blood circulation, blood stasis dispelling is promoted blood circulation, thus utilizes activating blood circulation to dissipate blood stasis method treatment cardiovascular and cerebrovascular disease to have certain effect.
Hyperlipidemia refers to a kind of disease disease that the lipid compositions such as the cholesterol in blood plasma, triglyceride, phospholipid and the most esterified fat acid increase.The traditional Chinese medical science thinks that hyperlipidemia belongs to " expectorant is turbid ", " expectorant numbness " category, is due to polyphagia greasy and surfeit flavour, and the thing of delicious food all heat fire-transformation make us fullness in the epigastrium and abdomen, and the most raw expectorant is turbid, causes organ function to decline, and causes substance metabolism and be disturbed completely.The internal organs relevant with blood lipid metabolism have: liver, kidney, small intestinal, stomach etc., are divided into deficiency of the liver and kindey, deficient qi and blood, the hepatic and renal YIN deficiency, qi stagnation blood stasis, phlegm resistance etc..Though traditional Chinese medical science ancient documents is without the title of " blood fat ", but existing " fat person ", " oils and fats ", " adipose membrane " etc. are recorded in Huangdi's Internal Classics.As " Ling Shu Miraculous Pivot or Divine Axis disorder of defensive QI " piece is said: " gas is sliding few for fat person, its serum." this is the record of fat person of touching upon the earliest.In successive dynasties doctor's nationality, clinical manifestation and method for the treatment of to complication such as similar hyperlipemia and the atherosclerosiss that thus causes, there is discussion in greater detail, see respectively in the diseases such as phlegm retention, cardiopalmus, dizziness, breast illness, apoplexy, angina pectoris, and unanimously think expectorant turbid be formed primary disease Etiological pathological factor.The medicine for the treatment of hypertension, hyperlipemia disease is a lot, is respectively arranged with its curative effect, but mostly with certain side effect, such as FUFANG JIANGYA PIAN, long-term taking is susceptible to senile dementia, for another example XUEZHINING, for the patient suffered from indiestion, diarrhoea reaction easily occurs.
Diabetes spp shows in commonly encountered diseases, frequently-occurring disease, current data, and developed country's diabetes prevalence is about 3-5%, China's diabetes prevalence has reached 1-2% the most, in many developing countries including China, the sickness rate of diabetes increases very fast, hence it is evident that exceed developed country.The diabetes multiple quality of life the most greatly affecting people, health care expenditures expenditure is also significantly increased, even can restrict socioeconomic sound development.Type ii diabetes belongs to motherland's medical science " diabetes " category, many relatively scorching the saying of the deficiency of YIN of traditional Chinese medical science traditional treatment.Chinese medicine is thought, vasculopathy of the lower extremity in diabetes change belongs to deficiency of both QI and YIN, blood vessels stasis of blood plug more, and acra loses supports " for the card of deficiency in origin and excess in superficiality, with deficiency of both QI and YIN for this, blood stasis pyretic toxicity is for marking ", " blood stasis due to qi deficiency, yang-energy does not reach for pathogenesis crucial ".
nullCN1679701A discloses a kind of by Radix Notoginseng、Pharmaceutical preparation for the treatment of cardiovascular and cerebrovascular disease that Flos Carthami is made and preparation method thereof，CN104138468A discloses the application in preparing blood lipid-lowering medicine of a kind of Chinese medicine composition，It is by made by the crude drug of following weight portion: Herba Portulacae 50 parts、Radix Ginseng 25-45 part、Radix Notoginseng 30-50 part、Rhizoma Chuanxiong 20-30 part、Folium Ginkgo 20-30 part、Hirudo 25-35 part、Radix Rhodiolae 25-35 part、Lignum Dalbergiae Odoriferae 15-25 part、Radix Astragali 20-30 part、Radix Rehmanniae Preparata 25-35 part、Radix Salviae Miltiorrhizae 10-20 part、Radix Paeoniae Rubra 10-20 part、Fructus Schisandrae Chinensis 5-15 part、Fructus Lycii 5-15 part，CN105055851A discloses a kind of Chinese medicine composition treating diabetes、Its preparation and application thereof，It is to use Radix Ginseng、Rhizoma Polygonati Odorati、Flos Carthami and Radix Notoginseng are made.
Cardiovascular and cerebrovascular disease, hyperlipidemia and diabetes are the most interrelated, while suffering from a kind of disease, generally also can there is the symptom of other two kinds of diseases in patient, particularly cardiovascular and cerebrovascular disease is closer with the relation of hyperlipidemia, medicine or the effect of above-mentioned patent application publication are general, or flavour of a drug are on the high side, or effect is single.Therefore, develop a kind of medicine with treatment cardiovascular and cerebrovascular disease, hyperlipidemia and diabetes evident in efficacy to be very important.
The present inventor is after Chinese medical discrimination of having concentrated on studies analyzes the reason of cardiovascular and cerebrovascular disease, hyperlipidemia and diabetes, and the accumulation of practice of touching upon according to motherland's medical use pharmacology, through rigorous compatibility, the new medicinal proved recipe of proposition.
Radix Notoginseng (Panax notoginseng (Buck) F.H.Chen) is the root of araliaceae ginseng plant, and main product, in the ground such as Yunnan, Guangxi, calls Radix Notoginseng, Radix Notoginseng, warm in nature, sweet in the mouth is bitter, cure mainly dissipating blood stasis hemostasis, subduing swelling and relieving pain, be used for spitting blood, spit blood, epistaxis, have blood in stool, metrorrhagia, traumatic hemorrhage, chest and abdomen twinge, tumbling and swelling.Study of pharmacy finds, the main active of Radix Notoginseng is Radix Notoginseng total arasaponins, containing saponin about 12% in its tuber, the most isolates 20 kinds of dammarane type saponin from each position of Radix Notoginseng.The most active to the research of the pharmacological action particularly cardio-cerebrovascular pharmacology effect of Radix Notoginseng total arasaponins; the arasaponin preparation that people extract from crude drug Radix Notoginseng is compared with crude drug in whole Radix Notoginseng; have steady quality, bioavailability is high, easy to use, act on the advantage rapid, toxicity is low and safety is good; it can lower surface activity of blood platelet, antioxidation, scavenging activated oxygen, improve blood circulation, anoxia enduring, therefore protected cardiac muscle, protects blood vessel endothelium, improves the effect such as cardiac function.
Flos Carthami (Cacthamus tinctonus.L) is the dry flower of feverfew Flos Carthami, nature and flavor are pungent, warm, GUIXIN, Liver Channel, have promoting blood circulation to restore menstrual flow, effect of eliminating stasis to stop pain, can treat amenorrhea, lump in the abdomen, difficult labour, stillborn fetus, disease that postpartum lochia can't go, blood stasis are had a pain, carbuncle, fall and reach damage etc..Research shows, the principle active component of Flos Carthami is present in its water-soluble portion, Carthamus yellow is the water soluble mixt containing multiple chalcone, pharmacological evaluation shows that it is the main effective active composition of Flos Carthami, there is coronary artery dilator, improve myocardial blood flow, reduce blood pressure, expand blood vessel, improve organ blood supply, anticoagulation, inhibition thrombosis, the multiple pharmacological effect such as anoxia enduring, antiinflammatory.
Herba Cistanches (Cistanche deserticola Y.C.Ma) is the fleshy stem of the dry zone scale leaf of orobanchaceae plant cistanche or Cistanche Tubulosa, when spring, Seedling was just unearthed or autumn excavates before frozen soil, removes stem apex, cutting, dries and get final product, warm in nature, sweet in the mouth, salty, return kidney, dog intestinal warp, cure mainly kidney-replenishing, benefiting essence-blood, loosening bowel to relieve constipation, for insufficiency of kidney-YANG, blood and essence asthenia, sexual impotence is infertile, soreness of the waist and knees, muscles and bones is unable, dryness of the intestine constipation.Research shows, the plurality of active ingredients of Herba Cistanches, such as multiple alkaloid, has the kidney invigorating, benefit essence, moisturizes, laxation, effect of blood pressure lowering.
The present invention uses Radix Notoginseng, Flos Carthami and Herba Cistanches to carry out specific compatibility as raw material, it is provided that plants to have and significantly treats cardiovascular and cerebrovascular disease, hyperlipidemia and the Chinese medicine composition of hyperglycemia function.
Summary of the invention
It is an object of the invention to provide a kind of effect and significantly there is treatment cardiovascular and cerebrovascular disease, hyperlipidemia and the Chinese medicine composition of hyperglycemia function.
The present invention solves the technical scheme of this technical problem:
A kind of have treatment cardiovascular and cerebrovascular disease, hyperlipidemia and the Chinese medicine composition of hyperglycemia function, raw material is by Radix Notoginseng extract, Flos Carthami extract and Herba Cistanches extract composition, the weight ratio of each raw material is: Radix Notoginseng extract: Flos Carthami extract: Herba Cistanches extract is 0.5-2: 1-5: 4-10.
Preferably, the weight ratio of each raw material is: Radix Notoginseng extract: Flos Carthami extract: Herba Cistanches extract is 0.5-1.5: 2-4: 6-8.
It is further preferred that the weight ratio of each raw material is: Radix Notoginseng extract: Flos Carthami extract: Herba Cistanches extract is 1: 3: 7.
The preparation method of described Radix Notoginseng extract is: take Radix Notoginseng coarse powder, crosses a sieve, adds 60% soak with ethanol of 6-8 times amount, and the time is 2-4h, heating and refluxing extraction, filter to get filtrate, repeat to extract twice, merging filtrate, decompression recycling ethanol, it is concentrated in vacuo, dry, pulverize, to obtain final product.
The preparation method of described Flos Carthami extract is: take flos carthami, adds the water of 8-10 times amount, is heated to 70-80 DEG C of immersion, and the time is 1-2h, filters to get filtrate after letting cool, and repeats to extract twice, merging filtrate, concentrating under reduced pressure, dry, pulverize, to obtain final product.
The preparation method of described Herba Cistanches extract is: takes Herba Cistanches pulverizing medicinal materials and crosses 100 mesh sieves, adds 60% ethanol of 5-10 times amount, is heated to 50-60 DEG C and extracts 2-4h, extracting solution centrifugation is taken supernatant, concentrating under reduced pressure, dry, pulverize, to obtain final product.
Invention also provides the preparation method of above-mentioned Chinese medicine composition, comprise the following steps:
(1) taking Radix Notoginseng coarse powder, cross a sieve, add 60% soak with ethanol of 6-8 times amount, the time is 2-4h, and heating and refluxing extraction filters to get filtrate, repeats to extract twice, merging filtrate, decompression recycling ethanol, be concentrated in vacuo, dry, pulverize, obtain Radix Notoginseng extract；
(2) taking flos carthami, add the water of 8-10 times amount, be heated to 70-80 DEG C of immersion, the time is 1-2h, mistake after letting cool
Filter to obtain filtrate, repeat to extract twice, merging filtrate, concentrating under reduced pressure, dry, pulverize, obtain Flos Carthami extract；
(3) take Herba Cistanches pulverizing medicinal materials and cross 100 mesh sieves, add 60% ethanol of 5-10 times amount, be heated to 50-60 DEG C and extract 2-4h, extracting solution centrifugation is taken supernatant, concentrating under reduced pressure, dry, pulverize, obtain Herba Cistanches extract；
(4) weigh each component by formula ratio, add pharmaceutically acceptable adjuvant, be prepared as tablet, capsule, granule, powder or oral liquid.
The Chinese medicine composition of the present invention can be any pharmaceutically useful dosage form, including tablet, capsule, oral liquid, syrup, granule, pill, powder, unguentum, sublimed preparation, injection, suppository, cream, spray, drop pill, patch, slow releasing preparation and controlled release preparation etc..
The form of oral liquid can be aqueous or oily solution, suspension, Emulsion, syrup or elixir, it can be containing conventional additive, including solvent such as water, ethanol etc., suspending agents such as sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl cellulose etc., emulsifying agent such as lecithin, anhydro sorbitol monooleate, arabic gum etc., preservative such as para hydroxybenzene methyl ester, propyl p-hydroxybenzoate, sorbic acid etc..
Oral solid formulation can be containing conventional excipient, such as binding agent, filler, diluent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can be coated the filler that applicable filler includes that cellulose, mannitol, lactose are similar with other if desired to tablet.Suitable disintegrating agent includes starch, polyvinylpyrrolidone and starch derivatives, such as sodium starch glycollate.Suitable lubricant includes magnesium stearate.Suitable wetting agent includes sodium lauryl sulphate.
Invention also provides the application in the medicine of cardiovascular and cerebrovascular diseases medicament, hyperlipidemia, hyperglycemia is treated in preparation of the described Chinese medicine composition.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is expanded on further.Should be understood that these embodiments are merely to illustrate the present invention rather than limit the scope of the present invention.The experimental technique of unreceipted actual conditions in the following example, generally according to normal condition or according to the condition proposed by manufacturer.Unless otherwise indicated, the most all of percent, ratio, ratio or number are by weight.
Unless otherwise defined, the same meaning that all specialties used in literary composition are familiar with one skilled in the art with scientific words.Additionally, any method similar or impartial to described content and material all can be applicable in the inventive method.Preferable implementation described in literary composition only presents a demonstration with material and is used.
Embodiment 1
Taking Radix Notoginseng coarse powder, cross a sieve, add 60% soak with ethanol of 7 times amount, the time is 3h, and heating and refluxing extraction filters to get filtrate, and repeats to extract twice, merging filtrate, decompression recycling ethanol, is concentrated in vacuo, dry, pulverize, obtains Radix Notoginseng extract；Taking flos carthami, add the water of 9 times amount, be heated to 70 DEG C of immersions, the time is 2h, filters to get filtrate after letting cool, and repeats to extract twice, merging filtrate, concentrating under reduced pressure, dry, pulverize, obtains Flos Carthami extract；Take Herba Cistanches pulverizing medicinal materials and cross 100 mesh sieves, add 60% ethanol of 8 times amount, be heated to 55 DEG C and extract 3h, extracting solution centrifugation is taken supernatant, concentrating under reduced pressure, dry, pulverize, obtain Herba Cistanches extract；Take Radix Notoginseng extract 100g, Flos Carthami extract 300g and Herba Cistanches extract 700g, mix with appropriate amount of starch, fully mix after sieving, be distributed into capsule, prepare capsule.
Embodiment 2
Taking Radix Notoginseng coarse powder, cross a sieve, add 60% soak with ethanol of 6 times amount, the time is 4h, and heating and refluxing extraction filters to get filtrate, and repeats to extract twice, merging filtrate, decompression recycling ethanol, is concentrated in vacuo, dry, pulverize, obtains Radix Notoginseng extract；Taking flos carthami, add the water of 8 times amount, be heated to 75 DEG C of immersions, the time is 1.5h, filters to get filtrate after letting cool, and repeats to extract twice, merging filtrate, concentrating under reduced pressure, dry, pulverize, obtains Flos Carthami extract；Take Herba Cistanches pulverizing medicinal materials and cross 100 mesh sieves, add 60% ethanol of 6 times amount, be heated to 60 DEG C and extract 4h, extracting solution centrifugation is taken supernatant, concentrating under reduced pressure, dry, pulverize, obtain Herba Cistanches extract；Take 80 parts of g of Radix Notoginseng extract, Flos Carthami extract 200g and Herba Cistanches extract 600g, use appropriate distilled water diluting, filter, add simple syrup, potassium sorbate, prepare oral liquid.
Embodiment 3
Taking Radix Notoginseng coarse powder, cross a sieve, add 60% soak with ethanol of 8 times amount, the time is 2h, and heating and refluxing extraction filters to get filtrate, and repeats to extract twice, merging filtrate, decompression recycling ethanol, is concentrated in vacuo, dry, pulverize, obtains Radix Notoginseng extract；Taking flos carthami, add the water of 10 times amount, be heated to 70 DEG C of immersions, the time is 1h, filters to get filtrate after letting cool, and repeats to extract twice, merging filtrate, concentrating under reduced pressure, dry, pulverize, obtains Flos Carthami extract；Take Herba Cistanches pulverizing medicinal materials and cross 100 mesh sieves, add 60% ethanol of 10 times amount, be heated to 50 DEG C and extract 2h, extracting solution centrifugation is taken supernatant, concentrating under reduced pressure, dry, pulverize, obtain Herba Cistanches extract；Take Radix Notoginseng extract 120g, Flos Carthami extract 400g and Herba Cistanches extract 800g, with appropriate amount of starch, Pulvis Talci and magnesium stearate, mixing, direct compression after sieving, prepare tablet.
Embodiment 4
Taking Radix Notoginseng coarse powder, cross a sieve, add 60% soak with ethanol of 7 times amount, the time is 3h, and heating and refluxing extraction filters to get filtrate, and repeats to extract twice, merging filtrate, decompression recycling ethanol, is concentrated in vacuo, dry, pulverize, obtains Radix Notoginseng extract；Taking flos carthami, add the water of 9 times amount, be heated to 75 DEG C of immersions, the time is 2h, filters to get filtrate after letting cool, and repeats to extract twice, merging filtrate, concentrating under reduced pressure, dry, pulverize, obtains Flos Carthami extract；Take Herba Cistanches pulverizing medicinal materials and cross 100 mesh sieves, add 60% ethanol of 8 times amount, be heated to 55 DEG C and extract 4h, extracting solution centrifugation is taken supernatant, concentrating under reduced pressure, dry, pulverize, obtain Herba Cistanches extract；Take Radix Notoginseng extract 100 parts; Flos Carthami extract 300g and Herba Cistanches extract 700g, adds dehydrated alcohol, stirs; make soft material; soft material is added in oscillating granulator and make wet granular, 50 DEG C of drying, granulate in heated-air circulation oven; add magnesium stearate; mixing, uses composite film packaging, inspection, prepares granule.
The embodiment 5 Chinese medicine composition of the present invention protective effect pharmacodynamic evaluation to myocardial ischemia
Take Wistar strain male rat 60, be randomly divided into six groups, i.e. negative control group, positive controls, comparative example group, high dose group, middle dosage group and low dose group, often group 10.The rat of negative control group does not carry out any process, uses normal saline gavage, 1mL/ days, continuous 4 days；Positive controls, comparative example group, high dose group, the rat of middle dosage group and low dose group first carries out open chest anesthetized, maintain and breathe, around left coronary artery between left auricle and pulmonary conus, ligature, after ligaturing 1 hour, positive controls rat normal saline gavage, 1mL/ days, continuous 4 days；Comparative example group rat is dissolved in 1mL normal saline with FUFANG DANSHEN PIAN 2g/kg/ days and carries out gavage, continuous 4 days；High dose group rat is dissolved in 1mL normal saline for 2g/kg/ days with the Chinese medicine composition of the embodiment of the present invention 1 and carries out gavage, continuous 4 days；Middle dosage group rat is dissolved in 1mL normal saline for 1g/kg/ days with the Chinese medicine composition of the embodiment of the present invention 1 and carries out gavage, continuous 4 days；Low dose group rat is dissolved in 1mL normal saline for 0.5g/kg/ days with the Chinese medicine composition of the embodiment of the present invention 1 and carries out gavage, continuous 4 days.Left coronary artery is again ligatured before animal is put to death, take out after injecting her the Wen orchid of 1% in ventricle, rinse with PBS, freeze 1 hour, after removing excess tissue, dye 30 minutes in 37 DEG C in 1%TTC, with weight method calculating myocardium ischemia hazardous area (her Wen Lan Weiran district), infarcted region (TTC Wei Ran district).
Result shows; negative control group has no myocardial infarction phenomenon in 8 hours; after positive controls irrigates 5 hours, myocardial infarction is obvious; and the high dose group of the Chinese medicine composition of the present invention and middle dosage group can be obviously reduced the myocardial infarct size of myocardial reperfusion rat; show that Chinese medicine composition of the present invention has good protective effect, shown in concrete outcome table 1 to the change of ischemic myocardial cells Reperfu-sion myocardium cell necrosis:
The change of table 1 each experimental group myocardial infarct size
| Group | Number of cases | Infarcted region weight/left ventricular mass (%) | Infarcted region weight/hazardous area weight (%) |
| Negative control group | 10 | 0 | 0 |
| Positive controls | 10 | 40.1±8.1 | 59.8±8.2 |
| Comparative example group | 10 | 35.4±6.4* | 52.1±7.1* |
| High dose group | 10 | 25.2±5.7** | 42.3±5.5**△ |
| Middle dosage group | 10 | 30.2±5.8* | 48.3±4.7* |
| Low dose group | 10 | 39.3±4.9 | 57.4±7.3 |
Note: compare with positive controls, * P ＜ 0.05, * * P ＜ 0.01, compares with comparative example group, △ P ＜ 0.05.
Embodiment 6 Chinese medicine composition of the present invention blood fat reducing pharmacodynamic evaluation
Take 20-22g female mice 60, after raising 5 days with normal feedstuff, be randomly divided into six groups, i.e. negative control group, positive controls, comparative example group, high dose group, middle dosage group and low dose group, often group 10.nullNegative control group is raised with normal feedstuff，Positive controls、Comparative example group，High dose group，Middle dosage group and low dose group are with normal feedstuff 92.5%、Sal 2%、Yolk powder 2%、Adeps Sus domestica 3%、The fed with high of cholesterol 0.5% proportioning，Each group mice is all after raising 7 days，Negative control group and positive controls normal saline gavage，Comparative example group is with FUFANG DANSHEN DIWAN 2g/kg/ days gavage，High dose group is dissolved in 1mL normal saline with the Chinese medicine composition in the embodiment of the present invention 1 and carries out gavage for 2g/kg/ days，Middle dosage group is dissolved in 1mL normal saline with the Chinese medicine composition in the embodiment of the present invention 1 and carries out gavage for 1g/kg/ days，Low dose group is dissolved in 1mL normal saline with the Chinese medicine composition in the embodiment of the present invention 1 and carries out gavage for 0.5g/kg/ days，Successive administration 42 days，Pluck eyeball after fasting 12h take blood and dissect，To TCH、TG and MDA is measured，Result is as shown in table 2.
The impact on mice plasma T-CHOL, triglyceride and mda content of the table 2 each experimental group
| Group | Number of cases | TCH(mmol/L) | TG(mmol/L) | MDA(mmol/L) |
| Negative control group | 10 | 1.56±0.23 | 1.21±0.12 | 9.73±2.22 |
| Positive controls | 10 | 3.46±0.48 | 1.52±0.21 | 12.01±2.34 |
| Comparative example group | 10 | 3.01±0.21** | 2.01±0.31** | 4.21±0.76** |
| High dose group | 10 | 1.94±0.24*** | 1.06±0.21** | 7.62±0.87** |
| Middle dosage group | 10 | 2.54±0.45** | 1.36±0.32** | 5.31±0.41** |
| Low dose group | 10 | 3.32±0.43 | 1.53±0.31 | 10.34±0.34 |
Note: compare *: P ＜ 0.05 with positive controls；*: P ＜ 0.01；* *: P ＜ 0.001.
Result shows, after being administered 42 days, the cholesterol of positive controls mice plasma significantly improves than negative control group, mice hypercholesterolemia model built mould success under this experiment condition is described, find simultaneously, the mice plasma cholesterol level of high dose group and middle dosage group is all substantially less than positive controls, and less than comparative example group, illustrates that the Chinese medicine composition of the present invention has obvious blood fat reducing, Lowering cholesterol effect.
Embodiment 7 Chinese medicine composition of the present invention hypoglycemic drug effect is evaluated
Take the SD male rat 10 of 180-200g, as blank group, give conventional feed to feed, separately take 80 and be only given the high glucose and high fat forage feed being made up of conventional feed 66.5%, sucrose 20%, Adeps Sus domestica 10%, cholesterol 2.5% and cholate 1%, 4 weeks pneumoretroperitoneum injection STZ 50mg/kg body weight.Blank group lumbar injection 0.1mol/L, pH4.4 citric acid sodium citrate buffer solution simultaneously.3rd day afterbody takes blood, detects blood glucose, chooses the rat of blood glucose value ＞ 10.0mmol/L for testing.Successful for modeling rat is randomly divided into 5 groups by blood glucose, i.e. positive controls, high dose group, middle dosage group, low dose group and comparative example group, often group 10.Wherein, the Chinese medicine composition of the high dose group embodiment of the present invention 1 was dissolved in 1mL normal saline with 2g/kg/ days and carries out gastric infusion, the Chinese medicine composition of the middle dosage group embodiment of the present invention 1 was dissolved in 1mL normal saline with 1g/kg/ days and carries out gastric infusion, the Chinese medicine composition of the low dose group embodiment of the present invention 1 was dissolved in 1mL normal saline with 0.5g/kg/ days and carries out gastric infusion, comparative example group is dissolved in 1mL normal saline with metformin group 200mg/kg/ days and carries out gastric infusion, positive controls carries out gastric infusion with 1mL normal saline, continuous 6 weeks.After last is administered, each group Rat Fast 12h, femoral artery takes blood, separates serum in 30min.With spectrophotometry glycolated hemoglobin (GHb), result is as indicated at 3, gavage glucose 2g/kg body weight afterwards, afterbody takes blood, 0 is measured by blood glucose meter, 0.5, the blood glucose value of 2h, and it is calculated as follows area (AUC) under blood glucose-time graph, AUC (mmol h/L)=Area under the curve of blood glucose=1/2 × (0 hours blood glucose value+0.5 hours blood glucose value) × 0.5+1/2 × (2 hours blood glucose value+0.5 hours blood glucose value) × 1.5=0.25 × (0 hours blood glucose value+4 × 0.5 hours blood glucose value+3 × 2 hours blood glucose value), result is as shown in table 4.
The impact on rat glycolated hemoglobin of the table 3 each experimental group
| Group | Number of cases | Glycolated hemoglobin |
| Blank group | 10 | 13.67±2.98** |
| Positive controls | 10 | 25.65±2.45 |
| Comparative example group | 10 | 17.43±2.89* |
| High dose group | 10 | 17.34±8.31* |
| Middle dosage group | 10 | 19.32±9.21* |
| Low dose group | 10 | 22.41±4.54 |
Note: compared with model group, * * p ＜ 0.01, * p ＜ 0.05
Result shows, compared with blank group, positive controls GHb significantly raises (p ＜ 0.01), compared with positive controls, comparative example group, high dose group, middle dosage group rat GHb substantially reduce (p ＜ 0.05), and medicine low dose group is then without significant difference (p ＞ 0.05).
The each experimental group of table 4 is on rat fasting blood-glucose and the impact of carbohydrate tolerance (GTT)
| Group | Initial blood glucose | Last fasting glucose | Blood glucose reduces | Carbohydrate tolerance |
| Blank group | 4.89±0.54** | 5.21±0.11** | -0.32±0.32 | 8.24±2.21** |
| Positive controls | 15.45±3.21 | 15.31±0.33 | 0.14±0.66 | 30.23±4.31 |
| Comparative example group | 15.41±2.75 | 12.32±5.98 | 3.09±7.56 | 25.34±3.87 |
| High dose group | 15.83±2.11 | 9.32±4.34 | 5.49±4.81* | 26.34±3.76 |
| Middle dosage group | 16.01±2.41 | 12.35±3.67 | 3.66±7.93 | 30.24±5.82 |
| Low dose group | 15.48±3.33 | 15.64±3.77 | -0.16±4.21 | 38.81±3.76 |
Note: compared with model group, * * p ＜ 0.01, * p ＜ 0.05
Result shows, compared with blank group, positive controls carbohydrate tolerance significantly raises (p ＜ 0.01), with positive controls ratio, comparative example group, high dose group, the carbohydrate tolerance of middle dosage group all occur in that reduction in various degree, wherein, medicine high dose group relatively model group substantially reduces (p ＜ 0.05), and low dose group is then without significant difference (p ＞ 0.05).
It follows that the high dose of Chinese medicine composition of the present invention, middle dose drug all have preferable therapeutical effect to type ii diabetes.
The foregoing is only presently preferred embodiments of the present invention, it is not limited to the substantial technological context of the present invention, the substantial technological content of the present invention is broadly to be defined in the right of application, any technology entities that other people complete or method, if with application right defined in identical, also or the change of a kind of equivalence, all it is covered by being considered among this right.
Claims (10)
1. one kind has treatment cardiovascular and cerebrovascular disease, hyperlipidemia and the Chinese medicine composition of hyperglycemia function, it is characterised in that raw material
By Radix Notoginseng extract, Flos Carthami extract and Herba Cistanches extract composition.
Chinese medicine composition the most according to claim 1, it is characterised in that the weight ratio of each raw material is: Radix Notoginseng extract:
Flos Carthami extract: Herba Cistanches extract is 0.5-2: 1-5: 4-10.
Chinese medicine composition the most according to claim 2, it is characterised in that the weight ratio of each raw material is: Radix Notoginseng extract:
Flos Carthami extract: Herba Cistanches extract is 0.5-1.5: 2-4: 6-8.
Chinese medicine composition the most according to claim 3, it is characterised in that the weight ratio of each raw material is: Radix Notoginseng extract:
Flos Carthami extract: Herba Cistanches extract is 1: 3: 7.
5. according to the Chinese medicine composition described in any one of claim 1-4, it is characterised in that the dosage form of described Chinese medicine composition is
Tablet, capsule, granule, powder or oral liquid.
6. according to the Chinese medicine composition described in any one of claim 1-5, it is characterised in that the preparation side of described Radix Notoginseng extract
Method is: take Radix Notoginseng coarse powder, crosses a sieve, adds 60% soak with ethanol of 6-8 times amount, and the time is 2-4h, heating and refluxing extraction,
Filter to get filtrate, repeat to extract twice, merging filtrate, decompression recycling ethanol, be concentrated in vacuo, dry, pulverize, to obtain final product；Institute
The preparation method stating Flos Carthami extract is: take flos carthami, adds the water of 8-10 times amount, is heated to 70-80 DEG C of immersion, time
For 1-2h, filter to get filtrate after letting cool, repeat to extract twice, merging filtrate, concentrating under reduced pressure, dry, pulverize, to obtain final product；Institute
The preparation method stating Herba Cistanches extract is: takes Herba Cistanches pulverizing medicinal materials and crosses 100 mesh sieves, adds 60% ethanol of 5-10 times amount, heating
Extract 2-4h to 50-60 DEG C, extracting solution centrifugation is taken supernatant, concentrating under reduced pressure, dry, pulverize, to obtain final product.
7. according to the preparation method of the Chinese medicine composition described in any one of claim 1-6, it is characterised in that comprise the following steps:
(1) taking Radix Notoginseng coarse powder, cross a sieve, add 60% soak with ethanol of 6-8 times amount, the time is 2-4h, is heated to reflux carrying
Take, filter to get filtrate, repeat to extract twice, merging filtrate, decompression recycling ethanol, be concentrated in vacuo, dry, pulverize, obtain three
Seven extracts；
(2) taking flos carthami, add the water of 8-10 times amount, be heated to 70-80 DEG C of immersion, the time is 1-2h, mistake after letting cool
Filter to obtain filtrate, repeat to extract twice, merging filtrate, concentrating under reduced pressure, dry, pulverize, obtain Flos Carthami extract；
(3) take Herba Cistanches pulverizing medicinal materials and cross 100 mesh sieves, add 60% ethanol of 5-10 times amount, be heated to 50-60 DEG C and extract 2-4h,
Extracting solution centrifugation is taken supernatant, concentrating under reduced pressure, dry, pulverize, obtain Herba Cistanches extract；
(4) weigh each component by formula ratio, add pharmaceutically acceptable adjuvant, be prepared as tablet, capsule, granule,
Powder or oral liquid.
8. the application in preparation treatment cardiovascular and cerebrovascular diseases medicament of the Chinese medicine composition described in any one of claim 1-6.
9. the application in preparation treatment high blood cholesterol drug of the Chinese medicine composition described in any one of claim 1-6.
10. the application in preparation treatment antihyperglycemic drug of the Chinese medicine composition described in any one of claim 1-6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610300262.9A CN105963369A (en) | 2016-04-30 | 2016-04-30 | Traditional Chinese medicine composition with functions for treating cardiovascular and cerebrovascular diseases, hyperlipidemia, and hyperglycemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610300262.9A CN105963369A (en) | 2016-04-30 | 2016-04-30 | Traditional Chinese medicine composition with functions for treating cardiovascular and cerebrovascular diseases, hyperlipidemia, and hyperglycemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105963369A true CN105963369A (en) | 2016-09-28 |
Family
ID=56991450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610300262.9A Pending CN105963369A (en) | 2016-04-30 | 2016-04-30 | Traditional Chinese medicine composition with functions for treating cardiovascular and cerebrovascular diseases, hyperlipidemia, and hyperglycemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105963369A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1500499A (en) * | 2002-11-12 | 2004-06-02 | 昆明杉榆生物技术有限公司 | Compound formulation of adjusting, curing or improving blood function |
| CN1679701A (en) * | 2005-01-28 | 2005-10-12 | 北京阜康仁生物制药科技有限公司 | Medicinal preparation containing notoginseng and saflower for treating cardio-cerebral blood diseases and its preparing method |
| CN103006769A (en) * | 2013-01-05 | 2013-04-03 | 山东沃华医药科技股份有限公司 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
-
2016
- 2016-04-30 CN CN201610300262.9A patent/CN105963369A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1500499A (en) * | 2002-11-12 | 2004-06-02 | 昆明杉榆生物技术有限公司 | Compound formulation of adjusting, curing or improving blood function |
| CN1679701A (en) * | 2005-01-28 | 2005-10-12 | 北京阜康仁生物制药科技有限公司 | Medicinal preparation containing notoginseng and saflower for treating cardio-cerebral blood diseases and its preparing method |
| CN103006769A (en) * | 2013-01-05 | 2013-04-03 | 山东沃华医药科技股份有限公司 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 栾庆芳: ""红花注射液与丹参注射液治疗冠心病疗效对比观察"", 《黑龙江医药科学》 * |
| 蔡向红: "《养生堂<本草纲目> 中药养生速查全书》", 31 March 2014, 天津科学技术出版社 * |
| 赵余庆，吴春福: "《食疗与保健食品原料功能因子手册》", 31 March 2013, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101612360B (en) | Medicine for treating hepatitis, hepatocirrhosis and liver cancer | |
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN105749179A (en) | Traditional Chinese medicine composition for treating metabolic syndrome | |
| CN102755596B (en) | Traditional Chinese medicine for treating phlegm-dampness hyperplasia of mammary glands and preparation method thereof | |
| CN105920514A (en) | Traditional Chinese medicinal composition for treating metabolic syndrome | |
| CN103736036A (en) | Drug for treating nonalcoholic fatty liver disease and preparation method thereof | |
| CN105311581A (en) | Traditional Chinese medicine composition for preventing and treating hyperplasia of mammary glands and preparation method thereof | |
| CN106173605A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Herba Dendrobii | |
| CN103989970A (en) | Traditional Chinese medicine composition and application thereof in preparation of medicines for treating hypertension | |
| CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
| CN105056192A (en) | Traditional Chinese medicine composition for treating myocardial infarction and application thereof | |
| CN104043058A (en) | Traditional Chinese medicinal preparation for treating kidney deficiency type lumbar disc herniation and preparation method thereof | |
| CN105343761A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN103099885A (en) | Soft capsules having acne removing function and preparation method thereof | |
| CN103768349B (en) | Application in preparation treatment cerebrovascular and relevant disease medicine for the four taste Fructus cinnamomi camphorae preparations | |
| CN105963369A (en) | Traditional Chinese medicine composition with functions for treating cardiovascular and cerebrovascular diseases, hyperlipidemia, and hyperglycemia | |
| CN103099886A (en) | Soft capsule helpful for improving intestinal and gastric functions and preparation method thereof | |
| CN109260403A (en) | A kind of Chinese medicine composition for treating cancer of pancreas | |
| CN104189615B (en) | Traditional Chinese medicine preparation for treating metrorrhagia and metrostaxis, and preparation method of traditional Chinese medicine preparation | |
| CN103417836B (en) | Chinese medicine composition for the treatment of tumor and preparation method thereof | |
| CN106177480A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Herba Dendrobii | |
| CN104906471A (en) | Medicine composition for treating cyclomastopathy and preparation method thereof | |
| CN104958596A (en) | Traditional Chinese medicine composition for hernia patient | |
| CN106173604A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Rhizoma Polygonati Odorati | |
| CN105031335A (en) | Medicament for nursing and treatment after microwave pulverization of gastric bezoars and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160928 |